Multiple STIs Could Be Detected with A Single Rapid Test
|
By LabMedica International staff writers Posted on 26 Apr 2016 |

Image: A disposable cartridge for testing for a sexually transmitted disease (Photo courtesy of Atlas Genetics).
One test that could detect four of the most common sexually transmitted infections (STIs) in 30 minutes and allow them to be rapidly treated is under development. A GBP150,000 grant has been awarded to develop the test that will detect STIs, including chlamydia and gonorrhea.
Testing kits have been sent out by the UK National Chlamydia Screening Program aimed at those aged under 25 who did not have symptoms but wished to know they are clear of the infection. Their samples were then sent away for testing and those who tested positive for Chlamydia were offered the opportunity to trial the new technology.
Chlamydia is the UK’s most common STI with about 100,000 cases diagnosed each year and people under 25 years old are most at risk. If untreated, it can have serious long-term health consequences, including infertility in women. In some areas, one in five people never get treatment for their infection and others wait a long time before coming back to a clinic.
The test is being developed by scientists at St George’s, University of London (UK) and Atlas Genetics (Trowbridge, UK). The STI multiplex combines tests for four major nucleic acid targets, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, without the need for microscopy. The test is run on the Atlas Genetics’ io system which is a fully automated solution, requiring minimal hands-on time. Following the addition of an unprocessed patient specimen on to the io Cartridge, the Cartridge is then inserted in to the io Reader.
Tariq Sadiq MD, chief investigator at St. George’s, leads the eSTI2 Consortium which has developed a new smartphone app which allows patients to access an electronic clinic, the eSexual Health Clinic, to get rapid online treatment for chlamydia infection once they were diagnosed. Using a secure National Health System (NHS) log in, the app included an online medical consultation, leading to an electronic prescription for antibiotics, which patients could collect at a high street pharmacy. The app also enabled the patients’ sexual partners to get treatment quickly and easily in the same way. A clinical helpline is available for patients who need advice or support.
Eventually the eSexual Health Clinic will link to a hand held diagnostic device for STIs is also being developed by the scientists. This will mean that a urine or swab sample from patients would not have to be sent away for analysis, but can be analyzed at home so patients would receive their results within half an hour and then get their care online without ever needing to see a doctor face to face or attend a clinic.
Related Links:
St George’s, University of London
Atlas Genetics
Testing kits have been sent out by the UK National Chlamydia Screening Program aimed at those aged under 25 who did not have symptoms but wished to know they are clear of the infection. Their samples were then sent away for testing and those who tested positive for Chlamydia were offered the opportunity to trial the new technology.
Chlamydia is the UK’s most common STI with about 100,000 cases diagnosed each year and people under 25 years old are most at risk. If untreated, it can have serious long-term health consequences, including infertility in women. In some areas, one in five people never get treatment for their infection and others wait a long time before coming back to a clinic.
The test is being developed by scientists at St George’s, University of London (UK) and Atlas Genetics (Trowbridge, UK). The STI multiplex combines tests for four major nucleic acid targets, Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium, without the need for microscopy. The test is run on the Atlas Genetics’ io system which is a fully automated solution, requiring minimal hands-on time. Following the addition of an unprocessed patient specimen on to the io Cartridge, the Cartridge is then inserted in to the io Reader.
Tariq Sadiq MD, chief investigator at St. George’s, leads the eSTI2 Consortium which has developed a new smartphone app which allows patients to access an electronic clinic, the eSexual Health Clinic, to get rapid online treatment for chlamydia infection once they were diagnosed. Using a secure National Health System (NHS) log in, the app included an online medical consultation, leading to an electronic prescription for antibiotics, which patients could collect at a high street pharmacy. The app also enabled the patients’ sexual partners to get treatment quickly and easily in the same way. A clinical helpline is available for patients who need advice or support.
Eventually the eSexual Health Clinic will link to a hand held diagnostic device for STIs is also being developed by the scientists. This will mean that a urine or swab sample from patients would not have to be sent away for analysis, but can be analyzed at home so patients would receive their results within half an hour and then get their care online without ever needing to see a doctor face to face or attend a clinic.
Related Links:
St George’s, University of London
Atlas Genetics
Latest Technology News
- New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
- Rapid Biosensor Detects Drug Sensitivity in Breast Tumors
- Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
- Online Tool Supports Family Screening for Inherited Cancer Risk
- Portable Breath Sensor Detects Pneumonia Biomarkers in Minutes
- New Electronic Pipette Enhances Workflows with Touchscreen Control
- AI Model Outperforms Clinicians in Rare Disease Detection
- AI-Driven Diagnostic Demonstrates High Accuracy in Detecting Periprosthetic Joint Infection
- Blood Test “Clocks” Predict Start of Alzheimer’s Symptoms
- AI-Powered Biomarker Predicts Liver Cancer Risk
- Robotic Technology Unveiled for Automated Diagnostic Blood Draws
- ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Channels
Clinical Chemistry
view channelNext Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Clinical laboratories continue to face staffing shortages, limited space, and growing test volumes that pressure chemistry and electrolyte workflows. Maintaining rapid turnaround times increasingly depends... Read more
Blood Metabolite Test Detects Early Cognitive Decline
Timely identification of individuals at risk of dementia remains difficult because symptoms commonly appear only after significant neurodegeneration. Accessible screening tools that flag subtle cognitive... Read moreMolecular Diagnostics
view channel
Immune Signatures in Blood Help Inform Cancer Risk in Lynch Syndrome
Lynch syndrome is a hereditary condition that increases risk for colorectal and endometrial cancers and often results in earlier-onset disease. Clinicians need better ways to stratify asymptomatic carriers... Read more
Genetic Marker Predicts Early Heart Failure in Pulmonary Arterial Hypertension
Pulmonary arterial hypertension is a progressive condition characterized by obstructed pulmonary blood flow and strain on the right heart, with half of patients dying within five years of diagnosis.... Read more
Genomic Subtyping Assays Identify High-Risk Early-Stage Breast Cancers
Racial survival disparities in early-stage breast cancer remain a persistent clinical concern in the United States, with Black women experiencing higher mortality despite similar treatments.... Read more
cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample
Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read moreHematology
view channel
Open Multi-Omics Platform Identifies Prognostic Subtypes in Blood Cancers
Blood cancers encompass diverse entities whose biology and clinical behavior are best understood through integrative analyses across large cohorts. However, multi‑omic datasets and outcomes information... Read more
AI-Powered Digital Workflow Standardizes Bone Marrow Aspirate Morphology
Bone marrow aspirate examination is central to diagnosing and monitoring blood cancers and other serious hematologic diseases, yet the process in many laboratories remains manual and highly dependent on... Read moreImmunology
view channelCombined Screening Approach Identifies Early Leprosy Cases
Leprosy remains a significant public health concern, with more than 200,000 new cases reported globally each year and early disease often escaping routine laboratory detection. In its initial phase, bacterial... Read more
Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection
Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read morePathology
view channel
AI Tool Predicts Chemotherapy Response in Small Cell Lung Cancer
Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Tumor-Specific Biomarker Predicts Neoadjuvant Immunotherapy Response in Gastric Cancer
Gastric cancer is the fifth most common malignancy and the fourth leading cause of cancer mortality worldwide, with China bearing nearly half of the global burden. Only a subset of patients benefit from... Read moreTechnology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read moreIndustry
view channelGlobal Partnership Aims to Streamline NGS Tumor Profiling in Oncology Trials
CellCarta and Pillar Biosciences announced a global, multi-year strategic partnership on April 2, 2026 to broaden access to operationally streamlined next-generation sequencing (NGS) tumor profiling for... Read more







